YU17796A - Kristalni oblik 2-metil-tieno-benzodiazepina, njegove farmaceutske formulacije i postupak za njegovo dobijanje - Google Patents

Kristalni oblik 2-metil-tieno-benzodiazepina, njegove farmaceutske formulacije i postupak za njegovo dobijanje

Info

Publication number
YU17796A
YU17796A YU17796A YU17796A YU17796A YU 17796 A YU17796 A YU 17796A YU 17796 A YU17796 A YU 17796A YU 17796 A YU17796 A YU 17796A YU 17796 A YU17796 A YU 17796A
Authority
YU
Yugoslavia
Prior art keywords
benzodiazepine
thieno
methyl
preparation
pharmaceutical formulations
Prior art date
Application number
YU17796A
Other languages
English (en)
Other versions
YU49478B (sh
Inventor
Arthur Charles Bunnell
Arnold Barry Hendriksen
Dean Samuel Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU17796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of YU17796A publication Critical patent/YU17796A/sh
Publication of YU49478B publication Critical patent/YU49478B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

Opisan je kristalni oblik 2-metil-tieno-benzodiazepina koji ima tipičnu X-zračnu difrakcionu šemu za supstance u sprašenom stanju, koja je predstavljena sledećim interpolarnim rastojanjima: d (A) 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007 Takođe su opisane njegove farmaceutske formulacije i postupak za njegovo dobijanje.
YU17796A 1995-03-24 1996-03-22 Polimorfni oblik ii olanzapina, njegove farmaceutske formulacije i postupak za njegovo dobijanje YU49478B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (2)

Publication Number Publication Date
YU17796A true YU17796A (sh) 1999-03-04
YU49478B YU49478B (sh) 2006-05-25

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
YU17796A YU49478B (sh) 1995-03-24 1996-03-22 Polimorfni oblik ii olanzapina, njegove farmaceutske formulacije i postupak za njegovo dobijanje

Country Status (49)

Country Link
US (1) US5736541A (sh)
EP (3) EP0733635B1 (sh)
JP (1) JPH11502535A (sh)
KR (1) KR100399688B1 (sh)
CN (1) CN1065536C (sh)
AP (1) AP828A (sh)
AR (2) AR002719A1 (sh)
AT (4) AT406771B (sh)
AU (1) AU706471B2 (sh)
BG (1) BG62619B1 (sh)
BR (1) BR9607790A (sh)
CA (1) CA2214005C (sh)
CH (1) CH690579A5 (sh)
CO (1) CO4650278A1 (sh)
CZ (1) CZ292688B6 (sh)
DE (4) DE69614426T2 (sh)
DK (4) DK1445259T3 (sh)
EA (1) EA000149B1 (sh)
EE (1) EE03489B1 (sh)
EG (1) EG23659A (sh)
ES (3) ES2159346T3 (sh)
FI (1) FI973750A (sh)
GB (1) GB2313835B (sh)
HK (1) HK1013988A1 (sh)
HU (1) HU224989B1 (sh)
IL (1) IL117610A (sh)
IS (1) IS1896B (sh)
LT (1) LT4349B (sh)
LU (1) LU90096B1 (sh)
LV (1) LV12018B (sh)
MY (1) MY114701A (sh)
NO (1) NO314663B1 (sh)
NZ (1) NZ306110A (sh)
OA (1) OA10510A (sh)
PA (1) PA8353701A1 (sh)
PE (1) PE44897A1 (sh)
PL (1) PL183723B1 (sh)
PT (3) PT733635E (sh)
RO (1) RO118872B1 (sh)
SE (1) SE9703205D0 (sh)
SI (4) SI0733635T1 (sh)
SK (1) SK284143B6 (sh)
SV (1) SV1996000031A (sh)
TR (1) TR199701017T1 (sh)
TW (2) TW442488B (sh)
UA (1) UA44765C2 (sh)
WO (1) WO1996030375A1 (sh)
YU (1) YU49478B (sh)
ZA (2) ZA962344B (sh)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU7013196A (en) * 1995-09-29 1997-04-17 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1997035583A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
JP2000507945A (ja) * 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
AU2542997A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Anesthetic method
WO1997035582A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266444C (en) * 1996-09-23 2007-01-09 Eli Lilly And Company Olanzapine dihydrate d
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CZ302367B6 (cs) * 1998-09-30 2011-04-13 Eli Lilly And Company 2-Methylthienobenzodiazepinový prípravek
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
NZ519926A (en) * 1999-12-28 2004-02-27 Cipla Ltd New polymorphic forms of olanzapine
IL154688A0 (en) * 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
US6906062B2 (en) 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004108700A1 (en) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
CA2551806A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
DE112005000641T5 (de) 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
WO2006073886A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
BRPI0608484E2 (pt) * 2005-03-21 2014-10-29 Reddys Lab Ltd Dr Processo de preparação da forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
AU2013305895B2 (en) * 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
CA2882563C (en) 2012-08-21 2022-11-29 Eric Hryhorenko Antibodies to risperidone haptens and use thereof
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
KR20240130825A (ko) 2022-01-20 2024-08-29 테바 파마슈티컬스 인터내셔널 게엠베하 올란자핀, 이의 조성물 및 이의 사용 방법
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ATE198891T1 (de) * 1992-05-29 2001-02-15 Lilly Co Eli Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
SI1445259T1 (sl) 2006-10-31
MY114701A (en) 2002-12-31
CA2214005A1 (en) 1996-10-03
TW513432B (en) 2002-12-11
ZA962342B (en) 1997-09-22
DE69630324T2 (de) 2004-07-29
GB9719819D0 (en) 1997-11-19
FI973750A0 (fi) 1997-09-22
PT1095941E (pt) 2004-02-27
HU224989B1 (en) 2006-05-29
SK121897A3 (en) 1998-03-04
ES2159346T3 (es) 2001-10-01
KR19980703188A (ko) 1998-10-15
AP828A (en) 2000-04-28
ATE251627T1 (de) 2003-10-15
AU5427996A (en) 1996-10-16
PL183723B1 (pl) 2002-07-31
SI1095941T1 (en) 2003-12-31
SE9703205L (sv) 1997-09-05
CN1065536C (zh) 2001-05-09
TW442488B (en) 2001-06-23
KR100399688B1 (ko) 2004-02-18
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
CZ300097A3 (en) 1997-12-17
EG23659A (en) 2007-03-26
SI9620040A (sl) 1998-06-30
BG101900A (en) 1999-03-31
ATA902196A (de) 2000-01-15
IL117610A0 (en) 1996-07-23
DK0733635T3 (da) 2001-10-08
RO118872B1 (ro) 2003-12-30
YU49478B (sh) 2006-05-25
ATE331719T1 (de) 2006-07-15
ZA962344B (en) 1997-09-22
ES2266719T3 (es) 2007-03-01
DK108997A (da) 1997-11-12
PT733635E (pt) 2001-12-28
SK284143B6 (sk) 2004-10-05
LV12018A (lv) 1998-04-20
BG62619B1 (bg) 2000-03-31
IS4564A (is) 1997-09-22
AR002719A1 (es) 1998-04-29
US5736541A (en) 1998-04-07
HK1013988A1 (en) 1999-09-17
CA2214005C (en) 2001-07-03
LT97148A (en) 1998-01-26
LV12018B (en) 1998-09-20
IL117610A (en) 2001-08-26
EE9700232A (et) 1998-04-15
BR9607790A (pt) 1998-07-07
CZ292688B6 (cs) 2003-11-12
ATE204280T1 (de) 2001-09-15
HUP9802824A3 (en) 2000-01-28
PL322501A1 (en) 1998-02-02
HUP9802824A2 (hu) 1999-06-28
TR199701017T1 (xx) 1998-01-21
CO4650278A1 (es) 1998-09-03
NZ306110A (en) 1998-09-24
DE69636313D1 (de) 2006-08-10
DE69636313T2 (de) 2007-05-31
PE44897A1 (es) 1997-10-22
AT406771B (de) 2000-08-25
OA10510A (en) 2002-04-24
SI0733635T1 (en) 2002-06-30
CH690579A5 (de) 2000-10-31
DK1445259T3 (da) 2006-10-16
EP1095941A1 (en) 2001-05-02
FI973750A (fi) 1997-09-22
CN1179160A (zh) 1998-04-15
GB2313835B (en) 1998-09-16
LU90096B1 (fr) 1997-07-22
DE19681286T1 (de) 1998-04-02
EP1445259A1 (en) 2004-08-11
UA44765C2 (uk) 2002-03-15
DE69614426T2 (de) 2002-05-23
SV1996000031A (es) 1998-03-27
EA199700262A1 (ru) 1998-02-26
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
EA000149B1 (ru) 1998-10-29
EP0733635B1 (en) 2001-08-16
SE9703205D0 (sv) 1997-09-05
NO314663B1 (no) 2003-04-28
DE69630324D1 (de) 2003-11-13
DK1095941T3 (da) 2004-02-16
NO974365L (no) 1997-09-22
DE69614426D1 (de) 2001-09-20
IS1896B (is) 2003-10-20
JPH11502535A (ja) 1999-03-02
SI9620040B (sl) 2002-02-28
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
AU706471B2 (en) 1999-06-17
EP1445259B1 (en) 2006-06-28
MX9707183A (es) 1997-11-29
EE03489B1 (et) 2001-08-15
ES2208220T3 (es) 2004-06-16
GB2313835A (en) 1997-12-10
LT4349B (lt) 1998-05-25
EP1095941B1 (en) 2003-10-08
EP0733635A1 (en) 1996-09-25

Similar Documents

Publication Publication Date Title
YU17796A (sh) Kristalni oblik 2-metil-tieno-benzodiazepina, njegove farmaceutske formulacije i postupak za njegovo dobijanje
DK161708C (da) 11beta-aryloestradiener, deres anvendelse, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater med indhold deraf
BR1100019A (pt) Peptìdeo, compostos, composição farmacêutica, e, método de preparar compostos
NO980209L (no) Ny fremgangsmåte for fremstilling av amorft £R-(R*,R*)|-2-(4-fluorfenyl)-<beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-£(fenylamino)karbonyl|-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1)
MA22668A1 (fr) Procede de preparation d'oxamides .
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
HUT50842A (en) Process for producing new diphosphonic acid derivatives and pharmaceutical compositions comprising same
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
GR3023936T3 (en) Heterocyclic alkylamides, process for their preparation and pharmaceutical compositions containing them
YU100302A (sh) Novi $g (y) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
ZA951227B (en) Camptothecin derivatives and process for their preparation
BG103225A (en) Stable nonhygroscopic crystalline form of n-[n-n-(4-piperidin-4-yl) butanoyl)-n-ethylgricyl] compounds
RU94022277A (ru) Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
IL96636A0 (en) Piperidine derivatives and pharmaceutical compositions containing them
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
AU661831B2 (en) 8-ene-19, 11beta -bridged steroids, their preparation and pharmaceutical formulations containing them
NO974155L (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
PT83472A (en) Process for preparing improved antiinflammatory compositions containing piroxicam
DE69431662D1 (de) Stabilisierte tablettenformulierung
PL286188A1 (en) Method of obtaining renine retarding aminooligohydroxy derivatives
MY106776A (en) Solid dosage forms of almokalant and processes for manufacture thereof.
ES2049186A1 (es) Procedimiento para la preparacion de nuevos derivados de benzofuranil-imidazol.
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
HUT60502A (en) Process for producing water-soluble salts of purpuromycin and pharmaceutical compositions comprising same